K
Kota Itahashi
Publications - 5
Citations - 567
Kota Itahashi is an academic researcher. The author has contributed to research in topics: Tumor microenvironment & Cancer research. The author has an hindex of 1, co-authored 2 publications receiving 91 citations.
Papers
More filters
Journal ArticleDOI
The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies.
Shogo Kumagai,Yosuke Togashi,Takahiro Kamada,Eri Sugiyama,Hitomi Nishinakamura,Yoshiko Takeuchi,Kochin Vitaly,Kota Itahashi,Yuka Maeda,Shigeyuki Matsui,Takuma Shibahara,Yamashita Yasuho,Takuma Irie,Ayaka Tsuge,Shota Fukuoka,Akihito Kawazoe,Hibiki Udagawa,Keisuke Kirita,Keiju Aokage,Genichiro Ishii,Takeshi Kuwata,Kenta Nakama,Masahito Kawazu,Toshihide Ueno,Naoya Yamazaki,Koichi Goto,Masahiro Tsuboi,Hiroyuki Mano,Toshihiko Doi,Kohei Shitara,Hiroyoshi Nishikawa +30 more
TL;DR: A biomarker based on PD-1 positivity of effector and regulatory T cells in the tumor microenvironment that accurately predicts the effectiveness of checkpoint blockade in patients is developed.
Journal ArticleDOI
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments.
Shogo Kumagai,Shohei Koyama,Kota Itahashi,Tokiyoshi Tanegashima,Yi-Tzu Lin,Yosuke Togashi,Takahiro Kamada,Takuma Irie,Genki Okumura,Hidetoshi Kono,Daisuke Ito,Rika Fujii,Sho Watanabe,Atsuo Sai,Shota Fukuoka,Eri Sugiyama,Gokuran Watanabe,Takuya Owari,Hitomi Nishinakamura,Daisuke Sugiyama,Yuka Maeda,Akihito Kawazoe,Hiroki Yukami,Keigo Chida,Yuuki Ohara,Tatsuya Yoshida,Yuki Shinno,Yuki Takeyasu,Masayuki Shirasawa,Kenta Nakama,Keiju Aokage,Jun Suzuki,Genichiro Ishii,Takeshi Kuwata,Naoya Sakamoto,Masahito Kawazu,Toshihide Ueno,Taisuke Mori,Naoya Yamazaki,Masahiro Tsuboi,Yasushi Yatabe,Takahiro Kinoshita,Toshihiko Doi,Kohei Shitara,Hiroyuki Mano,Hiroyoshi Nishikawa +45 more
TL;DR: In this paper , the balance of programmed death-1 (PD-1)-expressing CD8+ T cells and regulatory T (Treg) cells in the tumor microenvironment (TME) determines the clinical efficacy of PD-1 blockade therapy through the competition of their reactivation.
Journal ArticleDOI
Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape.
Yoshiko Takeuchi,Tokiyoshi Tanegashima,Eiichi Sato,Takuma Irie,Atsuo Sai,Kota Itahashi,Shogo Kumagai,Yasuko Tada,Yosuke Togashi,Shohei Koyama,Esra A. Akbay,Takahiro Karasaki,Keisuke Kataoka,Soichiro Funaki,Yasushi Shintani,Izumi Nagatomo,Hiroshi Kida,Genichiro Ishii,Tomohiro Miyoshi,Keiju Aokage,Kazuhiro Kakimi,Seishi Ogawa,Meinoshin Okumura,Masatoshi Eto,Atsushi Kumanogoh,Masahiro Tsuboi,Hiroyoshi Nishikawa +26 more
TL;DR: PD-1 blockade exerts antitumor effects by reinvigorating tumor antigen-specific CD8+ T cells, whereas neoantigens arising from gene alterations in cancer cells comprise critical tumor antigens in a...
Journal ArticleDOI
Regulatory T‐cell development in the tumor microenvironment
TL;DR: The selective deletion of tumor‐infiltrating Treg cells is important for successful Treg cell‐targeted therapies, providing effective antitumor immunity without inducing deleterious autoimmune disorders.
Journal ArticleDOI
BATF epigenetically and transcriptionally controls the activation program of regulatory T cells in human tumors
Kota Itahashi,Takuma Irie,Junichiro Yuda,Shogo Kumagai,Tokiyoshi Tanegashima,Yi-Tzu Lin,Sho Watanabe,Yasushi Goto,Jun Suzuki,Keiju Aokage,Masahiro Tsuboi,Yosuke Minami,Genichiro Ishii,Yuichiro Ohe,Wataru Ise,Tomohiro Kurosaki,Yutaka Suzuki,Shohei Koyama,Hiroyoshi Nishikawa +18 more
TL;DR: It is shown that Treg cells in the TME of human lung cancers harbored a completely different open chromatin profile compared with CD8+ T cells, conventional CD4+ T Cells in theTME, and peripheral TReg cells, which can be applied in the development of Treg cell-targeted therapies.